Viewpoint Press Release Archive
In 2023 Viewpoint Molecular Targeting merged with Isoray. Access the archived Press Releases from Viewpoint Molecular Targeting.
Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)
Three poster presentations from Perspective Therapeutics’ scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 203Pb manufacturing, and In Vivo Distribution of Recoiled 213Bi from [225Ac]Ac-DOTATATE RICHLAND, WASHINGTON & CORALVILLE, Iowa, May 24, 2023 — Perspective Therapeutics, Inc. (“Perspective” or “the Company”)...
Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
Additional CDMO capabilities added to increase availability of clinical trial product in the US Phase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and VMT-01 for melanoma RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX),...
Perspective Therapeutics Announces Changes to the Board of Directors
Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the Committee Michael McCormick announced his resignation and amicable departure from the Board of Directors RICHLAND, WA & CORALVILLE, IA,...
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator...
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
The combination delivers the promise of bringing powerful new perspectives to the rapidly emerging field of Alpha-Particle radiopharmaceuticals RICHLAND, Wash. & CORALVILLE, Iowa–(BUSINESS WIRE)–Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular...
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent
In early December, VMT-α-NET, the Company’s lead drug for the treatment of neuroendocrine tumors was administered to patients in India on a compassionate use basis, independent of a planned US trial No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and...
Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT
RICHLAND, Wash. & CORALVILLE, Iowa–(BUSINESS WIRE)–Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced they will hold an investor webcast Wednesday, October 19,...
Viewpoint Molecular Targeting Announces Two New Grant Awards of $2 Million Each
SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer Institute CORALVILLE, IA / October 11, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary...
Viewpoint Molecular Targeting Announces Appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs CORALVILLE, IA / October 4, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary...
Viewpoint Molecular Targeting Announces VMT- -NET Granted U.S. FDA Fast Track Destination for the Treatment of Neuroendocrine Tumors
CORALVILLE, IA / October 3, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of [212Pb]VMT-α-NET...
Viewpoint Molecular Targeting Announces Transformational Merger
CORALVILLE, IA / September 29, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology...
Viewpoint Molecular Targeting® to Present at the B. Riley Radiation Oncology Investor Day
Fireside chat with newly appointed CEO, Thijs Spoor, today, February 22 at 1:30 PM ET CORALVILLE, IA / February 22, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced that Thijs Spoor, Chief Executive...
